Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cost of Revenue for 2 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue changed N/A to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 402.74% year-over-year, with the annual reading at $2.4 million for FY2025, 402.74% up from the prior year.
  • Cost of Revenue for Q4 2025 was $2.4 million at Pyxis Oncology, up from $475000.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $2.4 million in Q4 2025, with the low at $475000.0 in Q1 2024.